These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32249202)

  • 1. Circulating tumour-derived KRAS mutations in pancreatic cancer cases are predominantly carried by very short fragments of cell-free DNA.
    Zvereva M; Roberti G; Durand G; Voegele C; Nguyen MD; Delhomme TM; Chopard P; Fabianova E; Adamcakova Z; Holcatova I; Foretova L; Janout V; Brennan P; Foll M; Byrnes GB; McKay JD; Scelo G; Le Calvez-Kelm F
    EBioMedicine; 2020 May; 55():102462. PubMed ID: 32249202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control.
    Le Calvez-Kelm F; Foll M; Wozniak MB; Delhomme TM; Durand G; Chopard P; Pertesi M; Fabianova E; Adamcakova Z; Holcatova I; Foretova L; Janout V; Vallee MP; Rinaldi S; Brennan P; McKay JD; Byrnes GB; Scelo G
    Oncotarget; 2016 Nov; 7(48):78827-78840. PubMed ID: 27705932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
    Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
    Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing.
    Macgregor-Das A; Yu J; Tamura K; Abe T; Suenaga M; Shindo K; Borges M; Koi C; Kohi S; Sadakari Y; Dal Molin M; Almario JA; Ford M; Chuidian M; Burkhart R; He J; Hruban RH; Eshleman JR; Klein AP; Wolfgang CL; Canto MI; Goggins M
    J Mol Diagn; 2020 Jun; 22(6):748-756. PubMed ID: 32205290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and Clinical Validation of Discriminatory Multitarget Digital Droplet PCR Assays for the Detection of Hot Spot KRAS and NRAS Mutations in Cell-Free DNA.
    Hussung S; Follo M; Klar RFU; Michalczyk S; Fritsch K; Nollmann F; Hipp J; Duyster J; Scherer F; von Bubnoff N; Boerries M; Wittel U; Fritsch RM
    J Mol Diagn; 2020 Jul; 22(7):943-956. PubMed ID: 32376474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer.
    Lee B; Lipton L; Cohen J; Tie J; Javed AA; Li L; Goldstein D; Burge M; Cooray P; Nagrial A; Tebbutt NC; Thomson B; Nikfarjam M; Harris M; Haydon A; Lawrence B; Tai DWM; Simons K; Lennon AM; Wolfgang CL; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    Ann Oncol; 2019 Sep; 30(9):1472-1478. PubMed ID: 31250894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of targeted deep sequencing for detecting circulating tumor DNA in pancreatic cancer patients.
    Park G; Park JK; Son DS; Shin SH; Kim YJ; Jeon HJ; Lee J; Park WY; Lee KH; Park D
    Sci Rep; 2018 Aug; 8(1):11631. PubMed ID: 30072705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinoma.
    Affolter KE; Hellwig S; Nix DA; Bronner MP; Thomas A; Fuertes CL; Hamil CL; Garrido-Laguna I; Scaife CL; Mulvihill SJ; Underhill HR
    Neoplasia; 2021 Sep; 23(9):859-869. PubMed ID: 34298235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction of a reference material panel for detecting
    Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
    J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell free DNA in patients with pancreatic adenocarcinoma: clinicopathologic correlations.
    Theparee T; Akroush M; Sabatini LM; Wang V; Mangold KA; Joseph N; Stocker SJ; Freedman A; Helseth DL; Talamonti MS; Kaul KL
    Sci Rep; 2024 Jul; 14(1):15744. PubMed ID: 38977725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of KRAS Mutations in Circulating Tumor DNA by Digital PCR in Early Stages of Pancreatic Cancer.
    Brychta N; Krahn T; von Ahsen O
    Clin Chem; 2016 Nov; 62(11):1482-1491. PubMed ID: 27591291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Tumor DNA Is an Accurate Diagnostic Tool and Strong Prognostic Marker in Pancreatic Cancer.
    Sellahewa R; Moghaddam SM; Lundy J; Jenkins BJ; Croagh D
    Pancreas; 2023 Mar; 52(3):e188-e195. PubMed ID: 37751379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enrichment technique to allow early detection and monitor emergence of KRAS mutation in response to treatment.
    Kitagawa Y; Okumura K; Watanabe T; Tsukamoto K; Kitano S; Nankinzan R; Suzuki T; Hara T; Soda H; Denda T; Yamaguchi T; Nagase H
    Sci Rep; 2019 Aug; 9(1):11346. PubMed ID: 31383871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
    Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
    PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapy.
    Wahl SGF; Dai HY; Emdal EF; Ottestad AL; Dale VG; Richardsen E; Halvorsen TO; Grønberg BH
    J Pathol Clin Res; 2021 May; 7(3):209-219. PubMed ID: 33502820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients.
    Cheng H; Luo G; Jin K; Fan Z; Huang Q; Gong Y; Xu J; Yu X; Liu C
    Cancer Med; 2020 Mar; 9(6):2153-2159. PubMed ID: 32017404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.
    Sivapalan L; Thorn GJ; Gadaleta E; Kocher HM; Ross-Adams H; Chelala C
    BMC Cancer; 2022 Apr; 22(1):369. PubMed ID: 35392854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer.
    Tjensvoll K; Lapin M; Buhl T; Oltedal S; Steen-Ottosen Berry K; Gilje B; Søreide JA; Javle M; Nordgård O; Smaaland R
    Mol Oncol; 2016 Apr; 10(4):635-43. PubMed ID: 26725968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing.
    Holm M; Andersson E; Osterlund E; Ovissi A; Soveri LM; Anttonen AK; Kytölä S; Aittomäki K; Osterlund P; Ristimäki A
    PLoS One; 2020; 15(11):e0239819. PubMed ID: 33237900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.